Myriad Genetics, Inc. (MYGN)

Myriad Genetics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Jun 30, 2020	Jun 30, 2019
Cash & Equivalents	96.9	132.1	56.9	257.4	163.7	93.2
Short-Term Investments	7.4	8.8	58	81.4	54.1	43.7
Cash & Cash Equivalents	104.3	140.9	114.9	338.8	217.8	136.9
Cash Growth	32.53%	22.63%	-66.09%	55.56%	59.09%	-24.20%
Receivables	118.1	114.3	101.6	91.3	71	138.6
Inventory	24.6	22	20.1	15.3	29.1	31.4
Other Current Assets	43.3	36.4	38	39.4	13.8	41.7
Total Current Assets	290.3	313.6	274.6	484.8	331.7	348.6
Property, Plant & Equipment	177.4	180.6	187.3	125.3	103	57.3
Long-Term Investments	0	0	54.8	59	37	54.9
Goodwill and Intangibles	627.9	636.9	666.5	643.3	932.9	1,102
Other Long-Term Assets	14.9	15.4	15.5	8.3	0	0
Total Long-Term Assets	820.2	832.9	924.1	835.9	1,073	1,214
Total Assets	1,111	1,147	1,199	1,321	1,405	1,563
Accounts Payable	33.1	25.8	28.8	29.6	21.7	33.3
Deferred Revenue	0	0	0	0	32.8	2.2
Current Debt	13.8	16.2	14.1	13	13.5	0
Other Current Liabilities	99.2	113.9	94.3	161.7	79	82.3
Total Current Liabilities	146.1	155.9	137.2	204.3	147	117.8
Long-Term Debt	133	135.9	130.9	79.3	281.3	233.5
Other Long-Term Liabilities	71.4	71.5	44.8	69.3	58.1	122.5
Total Long-Term Liabilities	204.4	207.4	175.7	148.6	339.4	356
Total Liabilities	350.5	363.3	312.9	352.9	486.4	473.8
Total Debt	146.8	152.1	145	92.3	294.8	233.5
Debt Growth	-9.16%	4.90%	57.10%	-68.69%	26.25%	2410.75%
Retained Earnings	-655.5	-629.5	-366.2	-254.2	-173.9	25.6
Comprehensive Income	-4.2	-3.7	-8.9	-5.1	-5.2	-5.4
Shareholders' Equity	760	783.2	885.8	967.8	918.2	1,089
Net Cash / Debt	-42.5	-11.2	-30.1	246.5	-77	-96.6
Net Cash Per Share	-0.47	-0.14	-0.37	3.16	-1.04	-1.27
Working Capital	144.2	157.7	137.4	280.5	184.7	230.8
Book Value Per Share	8.45	9.46	10.99	12.41	12.36	14.81

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).